Effects on growth after switching protease inhibitors to efavirenz in HIV-1-infected children.
Rosso
Raffaella
R
Di Biagio
Antonio
A
Dentone
Chiara
C
Bassetti
Matteo
M
Viscoli
Claudio
C
Parodi
Arianna
A
De Maria
Andrea
A
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D000293:Adolescent; D000480:Alkynes; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D048588:Benzoxazines; D002648:Child; D003521:Cyclopropanes; D005260:Female; D006128:Growth / Q000187:drug effects*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1; D006801:Humans; D008297:Male; D010078:Oxazines / Q000627:therapeutic use*
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D017320:HIV Protease Inhibitors; D010078:Oxazines; C098320:efavirenz